### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Responses   | )   |  |   |   |  |  |   |  |   |   |   |  |  |  |  |  |
|---|---|--|---|---|--|--|---|--|---|---|---|--|--|--|--|--|
| Name and Address of Reporting Person* Yeaton Howard                 |   |  |   | 2. Issuer Name and Ticker or Trading Symbol Akers Biosciences, Inc. [AKER]  |  |  |   |  |   |   | :   | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner   |  |  |  |  |
| (Last) (First) (Middle) C/O AKERS BIOSCIENCES, INC., 201 GROVE ROAD |   |  |   | 3. Date of Earliest Transaction (Month/Day/Year) 05/24/2019   |  |  |   |  |   |   | X Officer (give title below) Other (specify below) CEO, CFO   |  |  |  |  |  |
| RE NII  | (Street)  |  | 4. If A   | Amendm  | ent,   | Date (   | Origin  | ıal Fil  | ed(Montl  | n/Day/Year)   |   | X_Form fil   | ed by One Repo   | orting Person  | •  | le Line)   |
| ICE, 143  | (State)   | (Zip)  | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  |   |  |  |   |  |   |   |   |  |  |  |  |  |
| 1.Title of Security<br>(Instr. 3)                                   |   | 2. Transaction<br>Date<br>(Month/Day/Year)   | Exect<br>any  | Execution Date, if  |  | f Code<br>(Instr. 8)   |   |  | , i   |   | of (D)  | (D) Beneficially Owned Followin<br>Reported Transaction(s)   |  | ollowing   | Ownership<br>Form:   | 7. Nature of Indirect Beneficial   |
|   |   |  | (Mon  | nth/Day/Year)   |  | ode V  |   | Amour  | (A) or (D)  |   | (Instr. 3 and 4)  |  |  | or Indirect (I)  | Ownership<br>(Instr. 4)  |  |
| ock   |   | 05/24/2019   |   |   |  | A  | 4   |  | 7,500   |   |   | 30,000   |  |  | D  |  |
|   |   |  |   |   |  |  | t<br>quire  | the fo   | orm dis   | splays a  | curren<br>eficiall  | itly valid   | OMB con  |  |  |  |
|   |   |  | <i>e.g.</i> , p   | uts, calls  | , wa   | rrant  | s, opt  | ions,  | conver  | tible secu  | rities)   |  |  | 1  |  |  |
| nversion  | Date  | Execution Da any   | te, if Transaction Code   |   | ion  |  |   | and Expiration Date<br>(Month/Day/Year)  |   | Amo<br>Unde<br>Secu   | ount of<br>erlying<br>rities  |  | Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | Ownersh<br>Form of<br>Derivating<br>Security<br>Direct (I<br>or Indirects)   | Beneficial<br>Ownershij<br>(Instr. 4)  |  |
|   |   |  |   |   |  |  |   | Date   |   | Expiration  |   | Amount or  |  |  |  |  |
| R   | ddress of ard BBIOSCAD RE, NJ ( ity  ock  ort on a so  exercise to of ivative | didress of Reporting Per ard  (First) BBIOSCIENCES, I AD (Street) RE, NJ 08086 (State) ity  ock ort on a separate line for a s | didress of Reporting Person ard  (First) (Middle)  BBIOSCIENCES, INC., 201  AD  (Street)  RE, NJ 08086  (State) (Zip)  ity 2. Transaction Date (Month/Day/Year)  ock 05/24/2019  Table II - 1  oversion Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  3A. Deemed Execution Date (Month/Day/Year)  (Month/Day/Year) | didress of Reporting Person 2. It and 3. Date (Street) 4. If A Separate line for each class of securities by the proof of | Address of Reporting Person*  ard  2. Issuer Nar Akers Biose Akers Biose 3. Date of Ear 05/24/2019  3. Date of Ear 05/24/2019  4. If Amendm  RE, NJ 08086  (State)  2. Transaction Date (Month/Day/Year)  ock  05/24/2019  2A. Deemed Execution Data any (Month/Day/Y  ort on a separate line for each class of securities beneficiall  aversion Date (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls aversion Date (Month/Day/Year)  Akers Biose 3. Date of Ear 05/24/2019  2A. Deemed Execution Data any (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls any (Month/Day/Year)  (Month/Day/Year)  Akers Biose 3. Date of Ear 05/24/2019  4. If Amendm  Table II - Derivative Securities (e.g., puts, calls any (Month/Day/Year)  (Month/Day/Year) | Address of Reporting Person— ard  Address of Reporting Person— ard  Akers Bioscier  3. Date of Earliest 05/24/2019  4. If Amendment,  RE, NJ 08086  (State)  2. Transaction Date (Month/Day/Year)  Ock  05/24/2019  Table II - Derivative Securities beneficially over the content of the content o | Address of Reporting Person—  ard  Address of Reporting Person—  Akers Biosciences,  BIOSCIENCES, INC., 201  AD  (Street)  ALIf Amendment, Date of Earliest Trans 05/24/2019  ALIf Amendment, Date of Earliest Trans 05/24/2019  ALIf Amendment, Date of Execution Date of Execution Date, if Code (Inst (Month/Day/Year)  Ock  05/24/2019  AD  Table II - Derivative Securities Ac (e.g., puts, calls, warrant (e.g., puts, calls, warrant (Month/Day/Year)  ALIf Amendment, Date of Execution Date, if Code (Inst (Month/Day/Year)  AD  Table II - Derivative Securities Ac (e.g., puts, calls, warrant (e.g., puts, calls, warrant (A) of Code (Instr. 8)  Transaction Date (Month/Day/Year)  (Month/Day/Year)  AD  AD  AD  AD  AD  AD  Table II - Derivative Securities Ac (e.g., puts, calls, warrant (any (Month/Day/Year) (A) or Dispo of (D) (Instr. 8) | Address of Reporting Person Akers Biosciences, Inc.  3. Date of Earliest Transaction 05/24/2019  4. If Amendment, Date Origin Reporting Person  According Person  Akers Biosciences, Inc.  3. Date of Earliest Transaction 05/24/2019  4. If Amendment, Date Origin Recution Date, if any (Month/Day/Year)  According Person  Akers Biosciences, Inc.  3. Date of Earliest Transaction 05/24/2019  A Date Origin Reporting Person  Akers Biosciences, Inc.  3. Date of Earliest Transaction 05/24/2019  A Deemed Execution Date, if any (Month/Day/Year)  A Deemed Execution Date, if Transaction Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3)  A Deemed Execution Date, if Transaction Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) | Address of Reporting Person Address Biosciences, Inc. [AK Akers Biosciences, Inc. [AK | Address of Reporting Person 2. Issuer Name and Ticker or Trading Sy Akers Biosciences, Inc. [AKER]  BIOSCIENCES, INC., 201  AD  (Street)  4. If Amendment, Date Original Filed(Month Day O5/24/2019  Table I - Non-Derivative Street (Month/Day/Year)  AD  (Street)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date (Instr. 8)  (Month/Day/Year)  A 7,500  Table II - Derivative Securities Acquired, Disposed (e.g., puts, calls, warrants, options, conversion Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, options, conversion Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, options, conversion Date (Month/Day/Year)  (Month/Day/Year) | 2. Issuer Name and Ticker or Trading Symbol Akers Biosciences, Inc. [AKER]  3. Date of Earliest Transaction (Month/Day/Year)  6. BIOSCIENCES, INC., 201  AD  (Street)  4. If Amendment, Date Original Filed(Month/Day/Year)  6. State)  7. Table I - Non-Derivative Securities  6. A Table II - Derivative Securities Acquired, Disposed of (A) or Disposed of (D) (Instr. 8)  7. Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 8)  8. Transaction Date  (e.g., puts, calls, warrants, options, convertible securities Acquired (A) or Disposed of (D) (Instr. 8)  (Instr. 8)  8. Deemed Execution Date, if any (Month/Day/Year)  8. Table II - Derivative Securities Acquired, Disposed of, or Ben (C.g., puts, calls, warrants, options, convertible securities and Execution Date of Unoth/Day/Year)  8. Transaction Date (Month/Day/Year)  8. A Deemed Execution Date, if any (Month/Day/Year)  8. Transaction Date (Month/Day/Year)  9. Code V Amount (D)  9. Persons who response of the form displays a december of Unoth/Day/Year)  1. Table II - Derivative Securities Acquired, Disposed of, or Ben (C.g., puts, calls, warrants, options, convertible securities and Expiration Date (Month/Day/Year)  1. Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8)  1. Transaction Date (Month/Day/Year)  1. Transaction Date (Month/Day/Year) | Address of Reporting Person and Akers Biosciences, Inc. [AKER]  3. Date of Earliest Transaction (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year) (Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  5. Transaction Date (Month/Day/Year)  6. Code V Amount (A) or Disposed of (D) (Instr. 3, 4 and 5)  6. Ort on a separate line for each class of securities beneficially owned directly or indirectly.  7. Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially owned directly or indirectly.  8. Transaction Date (e.g., puts, calls, warrants, options, convertible securities)  8. Transaction Date (Instr. 8)  9. Code V Amount (D) Price (D) Price (Instr. 8)  10. Code V Amount (D) Price (Instr. 8)  11. Derivative Securities Acquired, Disposed of, or Beneficially owned directly or indirectly.  12. Transaction Date (Instr. 8)  13. Transaction Date (Instr. 8)  14. Assocrative Securities Acquired (Month/Day/Year)  15. Transaction Date (Month/Day/Year)  16. Date Exercisable and Expiration Date (Month/Day/Year)  17. Tiansaction Date (Instr. 8)  18. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3)  18. Transaction Date (Instr. 8)  18. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) | Akers Biosciences, Inc. [AKER]    Code   V   Amount   (D)   Price          | Actives of Reporting Person Actives of Reporting Person Actives Biosciences, Inc. [AKER]  2. Issuer Name and Ticker or Trading Symbol Actives Biosciences, Inc. [AKER]  3. Date of Earliest Transaction (Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  (Street)  5. Relationship of Rep (Che Director X Officer (give title belied)  A Date Original Filed(Month/Day/Year)  (A) Or Date Original Filed(Month/Day/Year)  (B) Date Original Filed(Month/Day/Year)  (Code Original Filed(Month/Day/Year)  (Code Original Filed(Month/Day/Year)  (Code Original Filed(Month/Day/Year)  (Code Original Filed(Month/Day/Year) | Akers Biosciences, Inc. [AKER]  BIOSCIENCES, INC., 201  Al. If Amendment, Date Original Filed(Month/Day/Year)  Al. If Ame | Akers Biosciences, Inc. [AKER]  BIOSCIENCES, INC., 201  AD  (Street)  AL If Amendment, Date Original Filed(Month/Day/Year)  AL Securities Acquired (A) or Code (A) or Disposed of (D) Price (D) Price (D) (Instr. 3 and 4)  AL A T,500 A S O.65  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL A T,500 A S O.65  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL A T,500 A S O.65  AL ORIGINAL SAME OF CODE (Instr. 4)  AL A T,500 A S O.65  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 3 and 4)  AL ORIGINAL SAME OF CODE (Instr. 4)  AL ORIGINA |

|   | Relationships |              |          |       |  |  |
|---|---------------|--------------|----------|-------|--|--|
| Reporting Owner Name / Address  | Director      | 10%<br>Owner | Officer  | Other |  |  |
| Yeaton Howard<br>C/O AKERS BIOSCIENCES, INC.<br>201 GROVE ROAD<br>THOROFARE, NJ 08086 |               |              | CEO, CFO |       |  |  |

## **Signatures**

| /s/ Howard R. Yeaton            | 05/30/2019 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date       |

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.